Auriga
Auriga USA is a research and trading platform that focuses on growth sectors within the Health Care and Technology verticals. We operate out of our main office in New York City, and also have satellite offices in Boston, San Francisco, Philadelphia, San Diego, and Washington D.C. This regional network helps us to keep abreast of key corporate developments, enhance client relationships, and provide more efficient product distribution to meet clients' investment needs. The firm is committed to providing our clients with critical information flow, investment ideas, and access to industry experts.
View Older Stories View More Recent Stories
-
Auriga Reiterates a 'Buy' on DSW Inc. (DSW); Expect Strong Q4 and Solid '12 Start
-
Auriga Maintains a 'Buy' on Lululemon Athletica Inc. (LULU); Q4 Preview
-
Auriga Reiterates a 'Buy' on 3SBio (SSRX); Raising PT on Strong Q4 and Promising JV
-
Auriga Reiterates a 'Buy' on Affymax, Inc. (AFFY); Raising PT Ahead of Peginesatide's March 27 PDUFA
-
Auriga Maintains a 'Buy' on Medifast (MED); Q4 Preview
-
Auriga Upgraded JinkoSolar (JKS) to Hold, Price Target Reduced to $5
-
Auriga maintains a 'Hold' on Canadian Solar (CSIQ) Bragging Shipment, Dragging Profit
-
Auriga Maintains a 'Buy' on Sequenom (SQNM); MaterniT21 off to a Good Start
-
Auriga Reiterates a 'Buy' on CPI Aerostructures (CVU); Raising PT After Strong Qtr
-
Auriga Cuts Estimates on Ducommun Inc (DCO) Following Tough Qtr; Underlying Business Showing Spark
-
Auriga Reiterates a 'Buy' on Medidata Solutions (MDSO); Not Getting Tangled, It's Still A Growth Story
-
NutriSystem (NTRI) Shares Down 10% on Disappointing Results; One Firm Initiates Coverage, Two Downgrade
-
Auriga Reiterates a 'Buy' on CPI Aerostructures (CVU); Q4 Preview
-
UPDATE - Auriga Downgraded Nutrisystem (NTRI) to 'Hold' Following Lowered '12 Guidance
-
Auriga Downgrades Nutrisystem (NTRI) to Hold
-
Streetinsider.com's Hot Lunchtime Reads 03/05: (AMD) (SODA) (AAPL) (BIG) (TGT)
-
Auriga Technical Takeaways: Near-Term US Dollar Trends Appear Bullish; Gold Outperforming Over Long-Term
-
Auriga Reiterates a 'Buy' on Dole (DOLE); Adjusting Estimates on Expected Lower Pricing in Q4 & Q1
-
Auriga Reiterates a 'Buy' on Quiksilver (ZQK); Expect Solid Q1 and 2H Growth
-
Auriga on Healthcare IT & Services: HIMSS Themes - Accountability, Data Exchange, Population Health & Analytics
-
Canaccord Genuity Maintains a 'Buy' on Spectrum Pharmaceuticals (SPPI); Mixed Q4 Results
-
Auriga Reiterates a 'Buy' on Medidata Solutions (MDSO); Q4 Preview
-
Auriga Maintains a 'Buy' on A.M. Castle (CAS); Remaining Constructive Despite EPS Miss
-
Auriga Reiterates a 'Buy' on Esterline Tech (ESL); Raising PT After Blow Out Qtr
-
Streetinsider.com's Hot Lunchtime Reads 03/01: (YGE) (NOK) (AAPL) (ABT) (EBAY)
-
Auriga Maintains a 'Hold' on Yingli Green Energy (YGE); All We See Is Red Through 2013
-
Auriga Reiterate a 'Buy' on Protalix BioTherapeutics (PLX); No Material Changes in 10-K
-
Auriga Reiterates a 'Buy' on Nutrisystem (NTRI); Q4 Preview: Expect Focus to be on 2012 Progress
-
Auriga Reiterates a 'Hold' on Kaman Corporation (KAMN); Stage Set for a Strong 2012; Raising PT
-
UPDATE - Auriga Downgraded ViroPharma (VPHM) to Hold; Q4 Results Ahead of Expectations, But Shares Look Fully Valued Now
-
Auriga Maintains a 'Buy' on First Solar (FSLR); 4Q11 Washout; Maintains 2012 Outlook
-
Auriga Reiterates a 'Hold' on Fresh Del Monte (FDP); Lowers PT & Estimates
-
Auriga Reiterates a 'Buy' on Collective Brands (PSS); Turnaround Underway
-
Auriga Downgrades ViroPharma (VPHM) to Hold, Maintains $34 Price Target
-
Auriga Upgrades Salix Pharmaceuticals (SLXP) to Buy
-
Streetinsider.com's Hot Lunchtime Reads 02/27: (AAPL) (DNDN) (SIRI) (C) (F) (EBAY)
-
Auriga Reiterates a 'Hold' on Fresh Del Monte (FDP); Q4 Preview: Improving Industry Conditions Could Help 2012 Outlook
-
Auriga Maintains a 'Buy' on Cisco (CSCO); New Acquisitions/Investments Signal Renewed Focus
-
Auriga Maintains a 'Hold' on Trina Solar (TSL); Sacrificing Margin for Volume
-
Auriga Reiterates a 'Hold' on HEICO (HEI); Record First-Quarter Revenue Offset by Margin Pressure
-
Auriga Raising Numbers on Dynamic Materials (BOOM); Looking For Better Entry Point
-
Auriga Maintains a 'Buy' on GrafTech International (GTI); Guidance Weak, But May Be Opportunity for L-T Investors
-
Auriga Maintains a 'Hold' on ISTA Pharmaceuticals (ISTA); Some M&A Premium Already Built-In
-
Streetinsider.com's Hot Lunchtime Reads 02/24: (GOOG) (GM)/(F) (AAPL) (DECK) (WYNN)
-
Auriga Reiterates a 'Buy' on Exact Sciences (EXAS); Raising PT After Q4 Review; Timelines on Track
-
Auriga Suggests Using Weakness on Deckers Outdoor (DECK) as Buying Opportunity; Expects Normalized Growth in 2013
-
Auriga Reiterates a 'Buy' on The Medicines Company (MDCO); Believe the Company is Well Positioned
-
Auriga Reiterates a 'Hold' on Boston Beer Company (SAM); 4Q11 & FY11 Exceeds Consensus, But Guidance Tempered
-
Auriga Reiterates a 'Hold' on Herbalife (HLF); Raising Numbers on Strong Q4
-
Auriga Maintains a 'Hold' on Community Health (CYH) on Legal Overhang; Cost Mgmt Drives 4Q EPS Beat

